Becton Dickinson & Co Stock Price, News & Analysis

BD (Becton, Dickinson and Company) announces its participation at the Bank of America Securities 2023 Health Care Conference on May 9, 2023, at 11:00 am Eastern Time. The live webcast of the presentation will be available on BD's investor relations website, and a replay will follow the event. BD, a leading global medical technology company, focuses on advancing health care through innovative solutions aimed at enhancing patient care and operational efficiency for health providers. With a workforce of approximately 77,000 employees, BD is committed to addressing critical global health challenges and improving outcomes. For more details, visit bd.com.

The Board of Directors of Becton, Dickinson and Company (BD) has declared a quarterly dividend of $0.91 per common share. This dividend will be payable on June 30, 2023, to shareholders on record as of June 9, 2023. The indicated annual dividend rate stands at $3.64 per share. BD remains a significant player in the global medical technology sector, focusing on enhancing health care delivery, diagnostics, and clinical process efficiency. With a workforce of 77,000, BD is committed to addressing global health challenges through innovation and collaboration, ensuring improved outcomes and access to health care.

BD (NYSE: BDX) has released a survey by The Harris Poll, revealing significant gaps in women's knowledge about testing and treatment options for sexually transmitted infections (STIs) compared to other vaginal infections. Conducted with over 1,000 U.S. women over 18, the survey found that while 77% feel knowledgeable about vaginal infections, only 60% understand STI treatment options. A notable 82% of women who have seen a healthcare provider wish for more education on STIs. The study highlights disparities in healthcare access and diagnosis, especially among women of color, with only 29% of Black women feeling adequately diagnosed after one visit. The survey emphasizes the urgent need for improved education and access to testing technologies, particularly as STIs represent a considerable public health challenge in the U.S.

LivaNova PLC (Nasdaq: LIVN) announced the resignation of CEO Damien McDonald, effective immediately. William A. Kozy, Chair of the Board, will serve as interim CEO while the company searches for a permanent replacement. Kozy brings significant experience from his career at Becton Dickinson and as Vice Chair at The Cooper Companies. The company also reported preliminary Q1 2023 revenue of $263 million, marking a 9% increase compared to $240 million in Q1 2022. LivaNova is committed to maintaining its focus on growth and innovation during this transition, with full results set to be released on May 3, 2023.

BD (NYSE: BDX) has launched the BD Prevue™ II System, an advanced ultrasound device aimed at improving peripheral IV placement. This technology addresses challenges in IV access by offering real-time needle depth indicators and compatibility with BD Cue™ Needle Tracking-enabled catheters. Studies suggest that leveraging ultrasound and needle tracking can enhance the safety and efficiency of vascular access procedures, which affect over 90% of hospitalized patients. The system is designed with user-friendly features to facilitate quick adoption by clinicians. BD continues to pursue its vision of a 'One-Stick Hospital Stay' to minimize patient discomfort and enhance IV therapy effectiveness.

BD (NYSE: BDX) announced that it will report its financial results for the second quarter of fiscal year 2023 on May 4, 2023. The results will be available at approximately 6:30 a.m. ET and will include summary financial information for the quarter ending March 31, 2023. An audio webcast hosted by management will follow at 8 a.m. ET on the same day, discussing financial results, operations, and strategic updates. For access, visit BD's investor relations website. BD is recognized as a global leader in medical technology, committed to enhancing healthcare delivery.

On April 3, 2023, Becton, Dickinson and Company (NYSE: BDX) announced the appointment of Michelle Quinn as Executive Vice President and General Counsel, effective April 1. Quinn, who joined BD in 2019, previously served as Acting General Counsel and Senior Vice President. She will lead the Law Group and report to Tom Polen, CEO. Quinn's extensive experience in healthcare legal functions is expected to support BD's business strategies and governance initiatives. She holds a Juris Doctor from Villanova University and a Bachelor of Arts from Colgate University.